Orbit rhabdomyosarcoma

Summary

Orbit rhabdomyosarcoma (MONDO:0002580) is a disease. A subtype of orbit sarcoma — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	orbit rhabdomyosarcoma
Mondo ID	MONDO:0002580
MeSH	C537605
DOID	DOID:3259
NCIT	C4543
SNOMED CT	254994000
UMLS	C0346347
MedGen	83419
GARD	0023174
Anatomy (UBERON)	UBERON:0004088
Is cancer (heuristic)	no

Also known as: orbital region rhabdomyosarcoma · orbital region rhabdomyosarcoma (disease) · rhabdomyosarcoma (disease) of orbital region · rhabdomyosarcoma of orbit · rhabdomyosarcoma of the orbit

Disease family

An umbrella term covering 2 Mondo subtypes.

Classification path: disease › human disease › disease by body system or component › musculoskeletal system disorder › musculoskeletal system cancer › bone cancer › skull cancer › orbital cancer › orbit sarcoma › orbit rhabdomyosarcoma

Subtypes (2): orbit embryonal rhabdomyosarcoma, orbit alveolar rhabdomyosarcoma

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 0.